Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
alantir Q3 revenue surged 63% YoY on booming defense orders; full-year guidance raised.

alantir Q3 revenue surged 63% YoY on booming defense orders; full-year guidance raised.

Bitget2025/11/04 01:46
By:Bitget

Palantir reported Q3 revenue of $1.18 billion, a surge of 63% year-over-year, beating analysts’ expectations of $1.09 billion. This marks the 21st consecutive quarter that PLTR has topped Wall Street estimates. The company also significantly raised its full-year revenue guidance to $4.40 billion, up from the previous range of $4.14–$4.15 billion—its third upward revision this year.

Palantir is experiencing unprecedented growth in its U.S. commercial segment, with revenue expected to exceed $1.433 billion, representing a 104% increase. However, U.S. government sales showed a slight sequential slowdown, rising 52% year-over-year (compared to 53% in Q2). After hours, Palantir’s stock initially jumped 7% before quickly pulling back.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million

RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.

智通财经2026/09/21 16:16